On May 20, 2020, Bharat Biotech and Thomas Jefferson University of Philadelphia announced an exclusive deal to develop a new vaccine candidate for COVID-19 invented at Jefferson. The novel vaccine was developed using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins. This was in part be-cause this vehicle or carrier vaccine is known to produce a strong immune response, and is ap-proved for the whole population including children and pregnant women.